Clinical trial
A Phase II Study of Gemcitabine in Transitional Cell Carcinoma of the Urothelium
NCT00191971 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Study of Gemcitabine in Transitional Cell Carcinoma of the Urothelium
- Lead sponsor
- Eli Lilly and Company
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- January 31, 2004
- Completion date
- September 30, 2006
- Enrollment
- 40
- Sites
- 12
Conditions
As the registry lists them; a condition with its own page is linked.